A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

Summary

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old. The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months. During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.

Timeline

Start

2021-09-21

Primary completion

2025-12-31

Completion

2026-02-02

Publications

• Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V; FIND-CKD Investigators. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. 2026 Jun 4. doi: 10.1056/NEJMoa2604625. Online ahead of print.
• Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. JAMA. 2026 Jun 5:e269923. doi: 10.1001/jama.2026.9923. Online ahead of print.
• Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12.
• Li Y, Feng J, Guo X, Zhang W, Yang T, Guan T, Xu B. Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study. BMC Nephrol. 2025 Jul 1;26(1):323. doi: 10.1186/s12882-025-04241-w.
• Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22.

Drugs

Indications